Collapsin response-mediator protein-5-IgG, Western blot, serum
Collapsin response-mediator protein-5-IgG, Western blot, serum-
Effective October 23, 2025, this test is currently unavailable due to limited clinical utility for this method. It is recommended to order a phenotype-specific autoimmune/paraneoplastic evaluation. For more information as well as phenotype-specific testing options, see Autoimmune Neurology Test Ordering Guide.
Vision loss
Cranial neuropathy
CRMP5
Myelopathy
CRMP-5
CV2
Evaluation of cases of chorea, vision loss, cranial neuropathy and myelopathy
Immediately following collection, mix sample by gently inverting 5 times
- Allow sample to clot for a minimum of 30 minutes
- Spin within two (2) hours of sample collection
Gold serum separator (SST) tube
- Allow sample to clot
- Spin within two (2) hours of sample collection
- Transfer serum to a Screw cap transfer vial/tube (Mayo T914), labelled as serum
Refrigerated (preferred) – 28 days
Ambient – 72 hours
Frozen – 28 days
- Gross hemolysis
- Gross icterus
- Gross lipemia
Western blot
Negative
A positive result confirms that a patient's subacute neurological disorder has an autoimmune basis, and is likely to be associated with a small-cell lung carcinoma (SCLC) or thymoma, which may be occult. A positive result has a predictive value of 90% for neoplasm (77% SCLC, 6% thymoma). Seropositivity is found in approximately 3% of patients who have SCLC with limited metastasis without evidence of neurological autoimmunity.